Business Units at the Rainmaker Group

Gabriel Holschneider is a Mexico-based executive who holds a juris doctor from Universidad Iberoamericana. Following several years spent working as an associate for SAI Law and Economics, Gabriel Holschneider founded the Rainmaker Group, where he currently serves as chairman. 

Headquartered in Mexico City, the Rainmaker Group provides risk mitigation, transfer, and retention consulting on an international scale. Founded in 2004, the firm is divided into four business units in order to best address the needs of clients: 

1. Alternative Risk Finance: a unit that focuses on addressing risk for clients through self-insurance, underwriting, reinsurance, actuarial work, and pension strategies.

2. Wealth Preservation: a unit that provides asset-based lending and socially responsible credit. 

3. Health Care: a unit that invests in health care sectors and startup incubation services.

4. Technology: a unit that supports coordination between the technology and financial markets through structured financing and other efforts.

Boston Children’s Hospital May Have Found Cure for Type 1 Diabetes

Gabriel Holschneider is an attorney, an entrepreneur, and the founder and president of Rainmaker Group. As a dedicated philanthropist, Gabriel Holschneider supports a number of charitable organizations, including Boston Children’s Hospital.

Researchers at Boston Children’s Hospital are hoping to commence clinical trials on a treatment that uses a patient’s blood cells to treat type 1 diabetes. The same procedure has proven to be successful for treating mice with type 1 diabetes, in that all the animals studied were cured for a short time and one-third were cured for life.

This new treatment has the potential to cure type 1 diabetes by changing the way the immune system functions. Similar studies have attempted to use immunotherapy to cure type 1 diabetes by using a patient’s blood cells to stimulate the immune system.

Researchers at Boston Children’s Hospital are currently working with scientists from the San Diego-based company Fate Therapeutics to design a pill that will modulate stem cells in the blood to treat type 1 diabetes. They have even had a meeting with the U.S. Food and Drug Administration in hopes of commencing a human clinical trial.